Chemed Q3 Revenue Rises 10.6%; Adjusted Diluted EPS Reaches $6.75
Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, and adjusted diluted EPS of $6.75, up 28.1%. VITAS saw growth, while Roto-Rooter had softer adjusted EBITDA. VITAS' gross margin rose 221 bps, and Roto-Rooter reacquired California franchise territories.
How this was made
The 30-second read
Why it matters
The earnings beat may trigger short‑term buying interest and could lift sector peers.
Market read
First‑report earnings release with material revenue and EPS beat, offering a clear trading catalyst for CHE and related healthcare service stocks.
What to watch
Medicare Cap billing limitations at VITAS may constrain future profitability if policy changes tighten.
Background
Chemed Corp (NASDAQ: CHE) provides hospice, home health, and related services. The Q3 2026 results were filed via an 8‑K on Oct. 27, 2026.
Ticker impact
Chemed Corp reported Q3 2026 revenue of $690.9M (+10.6% YoY) and adjusted diluted EPS of $6.75, a fresh earnings disclosure via an 8‑K filing.
likely upward pressure as the market prices in the earnings beat and higher guidance expectations
Revenue and EPS both exceeded prior quarter and year‑over‑year growth, with strong VITAS performance offsetting modest Roto‑Rooter margin dip.
Market effects
Positive for the healthcare services sector, especially home health and hospice providers.
U.S. small‑cap healthcare stocks may see modest gains.
Limited to investors tracking U.S. healthcare service firms.
Counterpoint
Margin compression at Roto‑Rooter and modest EBITDA growth could signal underlying cost pressures.
Key entities
- companyChemed Corp
U.S. listed provider of hospice and home health services.
- divisionVITAS Healthcare
Chemed's hospice subsidiary showing strong growth.
- divisionRoto‑Rooter
Chemed's plumbing services unit with slight margin decline.
